Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - XERIS PHARMACEUTICALS INC | a201910-kexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - XERIS PHARMACEUTICALS INC | a201910-kexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - XERIS PHARMACEUTICALS INC | a201910-kexhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 - XERIS PHARMACEUTICALS INC | a201910-kexhibit231.htm |
| EX-4.3 - EXHIBIT 4.3 - XERIS PHARMACEUTICALS INC | a201910-kexhibit43.htm |
| 10-K - 10-K - XERIS PHARMACEUTICALS INC | a2019form10-k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Xeris Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barry M. Deutsch, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company. |
Date: March 11, 2020
By: | /s/ Barry M. Deutsch |
Barry M. Deutsch | |
Chief Financial Officer | |
(Principal Financial Officer) | |